| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| MATK has a current Overall Rating of B (Positive). | 7 |
$25 |
| 28-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (MATK). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (MATK). | 5 |
$18 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | MARTEK BIOSCIENCES CORP (MATK=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | MARTEK BIOSCIENCES CORP (MATK=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for MATK. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: MARTEK BIOSCIENC -- MATK | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ABII , CELG , ENZN , KNDL , LIFE , MATK , ONTY , VRTX -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| MATK: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | MARTEK BIOSCIENCES CORPORATION (MATK=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of MARTEK BIOSCIENCES CORP including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
1.48% Nasdaq 
Research Reports
